At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.
Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.
We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.
IAG’s radiomics team headed by Dr. Faiq Shaikh has just published the first article that explores the role of Reporter Gene Imaging in the realm of translational medicine.
Proceeds to advance PIPE-505 in hearing loss and additional neuroregenerative programs focused on synaptogenesis, remyelination and axonal repair
In 2017, RBV Capital acquired an equity stake in an innovative UK-based company developing an asset for treating symptoms of multiple sclerosis
